Marshall Wace Asia’s Zimmer Biomet ZBH Stock Holding History

Marshall Wace Asia’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,977	Closed	-$2.09M	–	204
2020 Q4	$2.09M	Buy	+13,977	New	+$1.97M	0.04%	120

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace Asia's ZBH Position: Q1 2021 in Review

Marshall Wace Asia sold out of Zimmer Biomet (ZBH) in Q1 2021, closing a stake of 13,977 shares — an estimated $2.09M sold.

Marshall Wace Asia first reported a position in ZBH in Q4 2020 and held it in 1 quarter. The position peaked at $2.09M in Q4 2020. 1,029 funds tracked by Wall St. Rank hold ZBH as of Q1 2021.

Marshall Wace Asia reported no remaining Zimmer Biomet position as of Q1 2021 after selling out during the quarter.
Marshall Wace Asia sold 13,977 Zimmer Biomet shares in Q1 2021, an estimated $2.09M.
Marshall Wace Asia first reported a position in Zimmer Biomet in Q4 2020 and held it in 1 quarter.
Marshall Wace Asia's Zimmer Biomet position peaked at $2.09M in Q4 2020.
1,029 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2021.

Based on Marshall Wace Asia's 13F filing for Q1 2021, filed 17 May 2021.